Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Debt: 2015-2023

Historic Total Debt for Cartesian Therapeutics (RNAC) over the last 8 years, with Dec 2023 value amounting to $28.3 million.

  • Cartesian Therapeutics' Total Debt rose 7.79% to $28.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $28.3 million, marking a year-over-year increase of 7.79%. This contributed to the annual value of $28.3 million for FY2023, which is 7.79% up from last year.
  • Cartesian Therapeutics' Total Debt amounted to $28.3 million in Q4 2023, which was up 17.84% from $24.0 million recorded in Q2 2023.
  • In the past 5 years, Cartesian Therapeutics' Total Debt registered a high of $28.3 million during Q4 2023, and its lowest value of $14.8 million during Q2 2020.
  • Moreover, its 3-year median value for Total Debt was $25.7 million (2022), whereas its average is $25.8 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Total Debt slumped by 31.16% in 2020, and later skyrocketed by 70.04% in 2021.
  • Quarterly analysis of 5 years shows Cartesian Therapeutics' Total Debt stood at $18.9 million in 2019, then surged by 31.15% to $24.8 million in 2020, then climbed by 3.39% to $25.6 million in 2021, then increased by 2.45% to $26.3 million in 2022, then grew by 7.79% to $28.3 million in 2023.
  • Its last three reported values are $28.3 million in Q4 2023, $24.0 million for Q2 2023, and $26.4 million during Q1 2023.